Melbourne trial of adjuvant immunotherapy in operable large bowel cancer.
A controlled randomized clinical trial was undertaken to assess the ability of combined non-specific and specific immunotherapy to alter the disease-free interval and overall survival of patients with Stage B or C large bowel cancer. The immunotherapy consisted of a 2 year programme of vaccinations with BCG and neuraminidase-treated autologous tumour cells. Three hundred and one patients entered the trial. At 5 years of follow-up there is no evidence that this form of immunotherapy can alter either the disease-free interval or survival in this group of patients.
D000951:Antigens, Neoplasm / Q000008:administration & dosage; D001500:BCG Vaccine; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy; D009439:Neuraminidase / Q000494:pharmacology; D011897:Random Allocation; D012004:Rectal Neoplasms / Q000628:therapy*; D014734:Vibrio cholerae / Q000201:enzymology
D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D009439:Neuraminidase